PMID- 38479462
OWN - NLM
STAT- Publisher
LR  - 20240320
IS  - 1879-3649 (Electronic)
IS  - 1537-1891 (Linking)
VI  - 155
DP  - 2024 Mar 11
TI  - Performance of drug-coated balloons in coronary and below-the-knee arteries: 
      Anatomical, physiological and pathological considerations.
PG  - 107366
LID - S1537-1891(24)00091-0 [pii]
LID - 10.1016/j.vph.2024.107366 [doi]
AB  - Below-the-knee (infrapopliteal) atherosclerotic disease, which presents as 
      chronic limb-threatening ischemia (CLTI) in nearly 50% of patients, represents a 
      treatment challenge when it comes to the endovascular intervention arm of 
      management. Due to reduced tissue perfusion, patients usually experience pain at 
      rest and atrophic changes correlated to the extent of the compromised perfusion. 
      Unfortunately, the prognosis remains unsatisfactory with 30% of patients 
      requiring major amputation and a mortality rate of 25% within 1 year. To date, 
      randomized multicentre trials of endovascular intervention have shown that 
      drug-eluting stents (DES) increase patency rate and lower target lesion 
      revascularization rate compared to plain balloon angioplasty and bare-metal 
      stents. The majority of these trials recruited patients with focal infrapopliteal 
      lesions, while most patients requiring endovascular intervention have complex and 
      diffuse atherosclerotic disease. Moreover, due to the nature of the 
      infrapopliteal arteries, the use of long DES is limited. Following recent results 
      of drug-coated balloons (DCBs) in the treatment of femoropopliteal and coronary 
      arteries, it was hoped that similar effective results would be achieved in the 
      infrapopliteal arteries. In reality, multicentre trials have failed to support 
      the proposed hypothesis and no advantage was found in using DCBs in comparison to 
      plain balloon angioplasty. This review aims to explore anatomical, physiological 
      and pathological differences between lesions of the infrapopliteal and coronary 
      arteries to explain the differences in outcome when using DCBs.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Ramses, Rafic
AU  - Ramses R
AD  - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Institute of 
      Cardiology, Catholic University of the Sacred Heart, Rome, Italy; Division of 
      Biomedical Engineering, University of Glasgow, United Kingdom.
FAU - Kennedy, Simon
AU  - Kennedy S
AD  - School of Cardiovascular and Metabolic Health, University of Glasgow, United 
      Kingdom.
FAU - Good, Richard
AU  - Good R
AD  - School of Cardiovascular and Metabolic Health, University of Glasgow, United 
      Kingdom; West of Scotland Regional Heart & Lung Centre, Golden Jubilee National 
      Hospital, Glasgow, United Kingdom.
FAU - Oldroyd, Keith G
AU  - Oldroyd KG
AD  - School of Cardiovascular and Metabolic Health, University of Glasgow, United 
      Kingdom; West of Scotland Regional Heart & Lung Centre, Golden Jubilee National 
      Hospital, Glasgow, United Kingdom.
FAU - Mcginty, Sean
AU  - Mcginty S
AD  - Division of Biomedical Engineering, University of Glasgow, United Kingdom. 
      Electronic address: Sean.Mcginty@glasgow.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240311
PL  - United States
TA  - Vascul Pharmacol
JT  - Vascular pharmacology
JID - 101130615
SB  - IM
OTO - NOTNLM
OT  - Below-the-knee (BTK) arterial disease
OT  - Coronary artery disease (CAD)
OT  - Drug-eluting balloons (DEBs)
OT  - Lower extremity peripheral arterial disease (LEAD)
OT  - Paclitaxel-coated balloons (PCBs)
COIS- Declaration of competing interest We hereby state that this review manuscript has 
      not been previously published and is not under consideration for publication 
      elsewhere at the moment. We are unaware of any conflicts of interest related to 
      this publication, and there has been no substantial financial support for this 
      work that could have impacted its results. As the Corresponding Author, I affirm 
      that all named authors have read and approved the manuscript.
EDAT- 2024/03/14 00:43
MHDA- 2024/03/14 00:43
CRDT- 2024/03/13 20:25
PHST- 2023/09/17 00:00 [received]
PHST- 2024/02/24 00:00 [revised]
PHST- 2024/03/08 00:00 [accepted]
PHST- 2024/03/14 00:43 [pubmed]
PHST- 2024/03/14 00:43 [medline]
PHST- 2024/03/13 20:25 [entrez]
AID - S1537-1891(24)00091-0 [pii]
AID - 10.1016/j.vph.2024.107366 [doi]
PST - aheadofprint
SO  - Vascul Pharmacol. 2024 Mar 11;155:107366. doi: 10.1016/j.vph.2024.107366.